IRWD

#2705
Ironwood Pharmaceuticals, Inc. - Class A
4.14 USD
+13.42%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
4.09
4.20
年范围
0.53
5.78
日变化
+13.42%
每月变动
+20.35%
6个月变化
+168.83%
年变化
+578.69%
前一天收盘价
3.65
开盘价
4.12
买价
卖价
最低价
4.09
High
4.20
交易量
958
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 675.06 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
22.47
市销率
1.85

Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

新闻